Publications by authors named "K C Morley"

Article Synopsis
  • - Topiramate has shown effectiveness in reducing alcohol use and possibly lowering anxiety severity in patients with alcohol use disorder (AUD), compared to naltrexone, another medication used for AUD.
  • - In a study with 42 treatment-seeking AUD patients, participants were given either topiramate or naltrexone for 12 weeks, and their neural responses to an anxiety-inducing task were measured using fMRI after 6 weeks of treatment.
  • - The study found no major differences in brain activation between the two treatment groups, but it noted that changes in anxiety levels were linked to the brain's response to threat cues, providing insights into how these medications may work.
View Article and Find Full Text PDF

Background: Labeling color fundus photos (CFP) is an important step in the development of artificial intelligence screening algorithms for the detection of diabetic retinopathy (DR). Most studies use the International Classification of Diabetic Retinopathy (ICDR) to assign labels to CFP, plus the presence or absence of macular edema (ME). Images can be grouped as referrable or nonreferrable according to these classifications.

View Article and Find Full Text PDF

Current treatments for alcohol use disorders (AUD) have limited efficacy. Recently, Cannabidiol (CBD) has been examined in a multitude of clinical settings. Preclinical and clinical results suggest that CBD might be particularly well suited for the treatment of AUD and may reduce alcohol cue and stress-induced craving and alcohol seeking.

View Article and Find Full Text PDF

N-acetyl cysteine (NAC) is a potential pharmacotherapy for alcohol use disorder (AUD), but it is not known whether it modulates neural activation to alcohol cues or intrinsic functional connectivity. We investigated whether NAC attenuates (i) alcohol cue-elicited activation, and (ii) intrinsic functional connectivity compared to placebo in patients with AUD. In this preliminary study, twenty-three individuals (7 females) with moderate-severe AUD received daily NAC (2400 mg/day, n = 9), or a placebo (n = 14) for at least 2 weeks.

View Article and Find Full Text PDF

Engineering sesquiterpene synthases to form predefined alternative products is a major challenge due to their diversity in cyclization mechanisms and our limited understanding of how amino acid changes affect the steering of these mechanisms. Here, we use a combination of atomistic simulation and site-directed mutagenesis to engineer a selina-4(15),7(11)-diene synthase (SdS) such that its final reactive carbocation is quenched by trapped active site water, resulting in the formation of a complex hydroxylated sesquiterpene (selin-7(11)-en-4-ol). Initially, the SdS G305E variant produced 20% selin-7(11)-en-4-ol.

View Article and Find Full Text PDF